SOX9 and osteosarcoma: If SUMOylated, SOX9 cannot be ubiquitinated and degraded, making the activity of SENP2 necessary for SOX9 degradation and the consequent reduced osteosarcoma cell proliferation, thus characterizing this SENP as a tumor suppressor [128].